- Home
- HSCS vs CLDI Comparison
HSCS vs CLDI Comparison
Compare HSCS & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- CLDI
- Stock Information
- Founded
- HSCS 2007
- CLDI 2014
- Country
- HSCS United States
- CLDI United States
- Employees
- HSCS N/A
- CLDI N/A
- Industry
- HSCS Medical Specialities
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSCS Health Care
- CLDI Health Care
- Exchange
- HSCS Nasdaq
- CLDI Nasdaq
- Market Cap
- HSCS 9.9M
- CLDI 8.7M
- IPO Year
- HSCS 2022
- CLDI N/A
- Fundamental
- Price
- HSCS N/A
- CLDI $1.60
- Analyst Decision
- HSCS Strong Buy
- CLDI
- Analyst Count
- HSCS 2
- CLDI 0
- Target Price
- HSCS $10.50
- CLDI N/A
- AVG Volume (30 Days)
- HSCS 94.3K
- CLDI 142.9K
- Earning Date
- HSCS 09-11-2025
- CLDI 11-11-2025
- Dividend Yield
- HSCS N/A
- CLDI N/A
- EPS Growth
- HSCS N/A
- CLDI N/A
- EPS
- HSCS N/A
- CLDI N/A
- Revenue
- HSCS $6,250.00
- CLDI N/A
- Revenue This Year
- HSCS $13,968.97
- CLDI N/A
- Revenue Next Year
- HSCS $166.67
- CLDI N/A
- P/E Ratio
- HSCS N/A
- CLDI N/A
- Revenue Growth
- HSCS N/A
- CLDI N/A
- 52 Week Low
- HSCS $2.52
- CLDI $1.41
- 52 Week High
- HSCS $6.47
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- HSCS 53.94
- CLDI 44.27
- Support Level
- HSCS $3.57
- CLDI $1.41
- Resistance Level
- HSCS $3.80
- CLDI $1.68
- Average True Range (ATR)
- HSCS 0.17
- CLDI 0.08
- MACD
- HSCS 0.02
- CLDI 0.05
- Stochastic Oscillator
- HSCS 62.50
- CLDI 70.48
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.